Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Tarcocimab Tedromer and Tabirafusp Tedromer versus Aflibercept in wet age-related macular degeneration; status ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Tabirafusp Tedromer (Tabirafusp Tedromer)
• Tarcocimab Tedromer (Tarcocimab tedromer)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: ACTIVE_NOT_RECRUITING